Safety and tolerability of cariprazine in patients with acute bipolar mania: pooled analysis of 3 phase II/III pivotal studies

被引：0
|
作者：
Yatham, L. N. [1 ]
Vieta, E. [2 ]
Lu, K. [3 ]
Nagy, K. [4 ]
Laszlovszky, I. [4 ]
Earley, W. [3 ]
Durgam, S. [3 ]
机构：
[1] Univ British Columbia, Dept Psychiat, Mood Disorders Clin Res Unit, Vancouver, BC, Canada
[2] Univ Barcelona, Dept Psychiat, Barcelona, Spain
[3] Forest Res Inst, Jersey City, NJ USA
[4] Gedeon Richter Plc, Budapest, Hungary
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70681-9
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.2.d.023
引用
收藏
页码：S426 / S427
页数：2
相关论文
共 50 条
  • [21] The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia
    McIntyre, Roger S.
    Daniel, David G.
    Vieta, Eduard
    Laszlovszky, Istvan
    Goetghebeur, Pascal J.
    Earley, Willie R.
    Patel, Mehul D.
    CNS SPECTRUMS, 2023, 28 (03) : 319 - 330
  • [22] Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
    Diener, Hans Christoph
    McAllister, Peter
    Jurgens, Tim P.
    Kessler, Yoel
    Ning, Xiaoping
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Barash, Steve
    Silberstein, Stephen D.
    CEPHALALGIA, 2022, 42 (08) : 769 - 780
  • [23] Safety and Tolerability of Fremanezumab in Patients With Episodic and Chronic Migraine: a Pooled Analysis of Phase 3 Studies
    Vargas, Bert B.
    Ning, Xiaoping
    Kessler, Yoel
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    McAllister, Peter
    NEUROLOGY, 2020, 94 (15)
  • [24] Safety and Tolerability of Fremanezumab in Patients with Episodic and Chronic Migraine: A Pooled Analysis of Phase 3 Studies
    McAllister, Peter
    Ning, Xiaoping
    Kessler, Yoel
    Cohen, Joshua M.
    Campos, Verena Ramirez
    Yang, Ronghua
    ANNALS OF NEUROLOGY, 2020, 88 : S158 - S159
  • [25] Efficacy of cariprazine in patients with bipolar i mania by baseline symptom severity: a pooled, post hoc analysis
    Yatham, L.
    Earley, W.
    Cheng-Tao, C.
    Barabassy, A.
    BIPOLAR DISORDERS, 2017, 19 : 149 - 149
  • [26] Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Studies
    Hutchinson, S.
    Dodick, D. W.
    Treppendahl, C.
    Bennett, N. L.
    Yu, S.
    Guo, H.
    Trugman, J. M.
    HEADACHE, 2019, 59 : 120 - 120
  • [27] Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Studies
    Hutchinson, Susan
    Dodick, David W.
    Treppendahl, Christina
    Bennett, Nate
    Yu, Sung Yun
    Guo, Hua
    Trugman, Joel M.
    CEPHALALGIA, 2019, 39 : 31 - 31
  • [28] Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability From ACHIEVE I and ACHIEVE II Phase 3 Studies
    Hutchinson, Susan
    Dodick, David W.
    Treppendahl, Christina
    Bennett, Nathan L.
    Yu, Sung Yun
    Guo, Hua
    Trugman, Joel M.
    NEUROLOGY, 2020, 94 (15)
  • [29] Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies
    Kato, Jitsu
    Baba, Masayuki
    Kuroha, Masanori
    Kakehi, Yoshihiro
    Murayama, Emiko
    Wasaki, Yosuke
    Ohwada, Shoichi
    CLINICAL THERAPEUTICS, 2021, 43 (05) : 822 - +
  • [30] Categorical Improvement Across Bipolar Depression Symptoms: Pooled Analyses of Cariprazine Randomized Phase II/III Trials
    McIntyre, Roger
    Yatham, Lakshmi
    Vieta, Eduard
    Aronin, Lauren
    Nguyen, Binh
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 262 - 263
12345